Clinical Trials Browser

Phase 1/2 × INDUSTRY × patritumab deruxtecan × Clear all

NCT04165070 2026-03-16

MK-3475-01A

Phase 1/2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06445972 2026-03-16

MK-3475-06D

Phase 1/2 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06469944 2026-03-16

MK-3475-06C

Phase 1/2 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06596694 2026-03-16

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

Phase 1/2 Recruiting

Gastrointestinal

Gastrointestinal Neoplasms

NCT07286149 2026-03-16

MK-3475-01F

Phase 1/2 Recruiting

Lung Neoplasms

NCT06941272 2026-03-13

MK-9999-01C

Phase 1/2 Recruiting

Neoplasms

NCT06686394 2026-02-13

MK-1022-009

Phase 1/2 Recruiting

Breast Neoplasms

NCT02980341 2024-10-30

Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

Phase 1/2 Completed

182 enrolled 37 charts

Breast Neoplasms, Neoplasms